J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Sustainable change requires improved study design, market incentives, and patient involvement, write Kate Womersley and colleagues For too long, medical research has defaulted to male physiology, ...

The Cyprus issue, water scarcity issues and forest fires in the EU and developments in the Middle east will be among the ...

Health officials have highlighted a rise in incidents of Covid-19 on the island, in the wake of an alert issued by the ...

Everest Medicines unveils breakthroughs in AI+mRNA platform, reinforces global leadership in next-gen mRNA innovation: Hong Kong Monday, July 7, 2025, 10:00 Hrs [IST] Everest Medi ...

EU chief Ursula von der Leyen faces a grilling from lawmakers Monday ahead of a confidence vote she is all but certain to ...

EUROPEAN COMMISSION PRESIDENT Ursula von der Leyen is set to travel to Strasbourg, France today to address MEPs before a ...

The Department of Veterans Affairs partners with Big Pharma to fuel “treatment” that triggers the very suicides it claims to ...